Atom Investors’s Inhibrx INBX Stock Holding History

Atom Investors’s Portfolio INBX Stock Details INBX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$2.8M	Buy	29,594 +3,089	+12%	+$310K	0.25%	97
2026 Q1	$1.78M	Buy	+26,505	New	+$1.97M	0.13%	264

Other funds holding INBX

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return

Sanofi Paris, France $534M AUM 205.96% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return

HighTower Advisors Chicago, Illinois $104B AUM 28.3% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

SSA

Schonfeld Strategic Advisors New York $27.9B AUM 51.18% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Atom Investors's INBX Position: Q2 2026 in Review

Atom Investors increased its Inhibrx (INBX) stake by 12% in Q2 2026, buying an estimated $310K and bringing the position to 29,594 shares worth $2.8M. The position accounts for 0.25% of the portfolio, ranked #97.

Atom Investors first reported a position in INBX in Q1 2026 and has held it in 2 quarters since. 162 funds tracked by Wall St. Rank hold INBX as of Q2 2026.

Atom Investors held 29,594 shares of Inhibrx worth $2.8M as of Q2 2026.
Atom Investors bought 3,089 Inhibrx shares in Q2 2026, an estimated $310K.
Inhibrx made up 0.25% of Atom Investors's portfolio in Q2 2026, its #97 holding.
Atom Investors first reported a position in Inhibrx in Q1 2026 and has held it in 2 quarters since.
162 funds tracked by Wall St. Rank held Inhibrx as of Q2 2026.

Based on Atom Investors's 13F filing for Q2 2026, filed 14 Aug 2026.